Implementation of HybridArc treatment technique in preoperative radiotherapy of rectal cancer: dose patterns in target lesions and organs at risk as compared to helical Tomotherapy and RapidArc

• Main Authors: Gevaert Thierry, Engels Benedikt, Garibaldi Cristina, Verellen Dirk, Deconinck Peter, Duchateau Michael, Reynders Truus, Tournel Koen, De Ridder Mark
• Format: Article
• Language: English
• Published: BMC 2012-07-01
• Series: Radiation Oncology
• Subjects: HybridArc; Helical Tomotherapy; RapidArc; Simultaneous integrated boost; Preoperative radiotherapy; IMRT rectal cancer
• Online Access: http://www.ro-journal.com/content/7/1/120

<p>Abstract</p> <p>Purpose</p> <p>HybridArc is a novel treatment technique blending aperture-enhanced optimized arcs with discrete IMRT-elements, allowing selection of arcs with a set of static IMRT-beams. This study compared this new technique to helical Tomotherapy, and RapidArc, in preoperative radiotherapy of rectal cancer.</p> <p>Material and methods</p> <p>Twelve rectal cancer patients treated consecutively with Tomotherapy Hi-Art II system were simulated with HybridArc and RapidArc. Treatment plans were designed to deliver homogeneous dose of 46.0Gy to mesorectum and draining lymph nodes, with a simultaneous-integrated-boost to the primary tumor up to a total dose of 55.2Gy. Planning objectives were 95% of prescribed dose to 95% of PTVs, while minimizing the volume of small bowel receiving more than 15Gy (V15) and the mean bladder dose. Dose gradient towards simultaneous-integrated-boost (GI), calculated by dividing the volume receiving more then 52.4Gy (95% of PTV55.2Gy)to the volume of PTV55.2Gy, was kept below 1.5. Mean beam-on time and amount of MUs were also analyzed.</p> <p>Results</p> <p>PTV swere adequately covered by all plans. Significant advantage was found for Tomotherapy in sparing small bowel (V15 = 112.7cm³SD73.4cm³) compared to RapidArc (133.4cm³SD75.3cm³) and HybridArc (143.7cm³SD74.4cm³) (p < 0.01). The mean bladder dose was better with RapidArc (20.6GySD2.2Gy) compared to HybridArc (24.2Gy SD4.3Gy) and Tomotherapy (23.0GySD4.7Gy) (p < 0.01). The mean beam-on time was significantly lower (p < 0.01) for HybridArc (2.7min SD0.8) and RapidArc (2.5min SD0.5) compared to Tomotherapy (11.0min SD0.7). The total amount of MUs was significantly (p < 0.01) lower for RapidArc (547SD44)compared to HybridArc (949 SD153).</p> <p>Conclusions</p> <p>HybridArc is a feasible solution for preoperative RT with a simultaneous-integrated-boost in rectal cancer patients. It achieved similar PTV coverage with significant lower beam-on time, but less efficient in sparing small bowel and bladder compared to Tomotherapy and RapidArc. The added value of HybridArc is that the treatment modality can be implemented on every LINAC equipped with Dynamic-Conform-Arc and IMRT treatment techniques, while maintaining the same QA-schemes.</p>